Shame on Aesculap: A $38.5M Settlement Exposes Device Failures, Kickbacks, and Why Foreign Ortho Giants Hesitate on the U.S. Market
In a move that reeks of corporate damage control rather than genuine accountability, Aesculap Implant Systems (AIS), the Pennsylvania-based arm of German medtech giant B. Braun, announced today the resolution of long-pending federal investigations.
But let's call this what it is: a slap on the wrist disguised as closure, with AIS shelling out $38.5 million in a civil settlement under the False Claims Act, plus a non-prosecution agreement to dodge criminal charges.
Shame on Aesculap for peddling faulty knee implants and doling out kickbacks while patients suffered—and shame on a U.S. legal system that turns these scandals into protracted, expensive battles, scaring off international ortho players from fully committing to the world's largest market.
The saga dates back over a decade, rooted in AIS's Vega System Knee Implant, a product introduced in 2010 that promised innovation but delivered premature failures. According to the U.S. Department of Justice (DOJ), AIS knowingly sold these implants despite evidence of poor adhesion with bone cement, leading...
